logo
Professor screw it, let's do it — battle-hardened HIV researcher Francois Venter ready for another big fight

Professor screw it, let's do it — battle-hardened HIV researcher Francois Venter ready for another big fight

Daily Maverick06-07-2025
Professor Francois Venter refuses to pull his punches, and he has publicly excoriated both the President and the health minister for their inaction on the HIV funding crises. As Sean Christie quickly learnt, that's just how one of the country's top HIV researchers rolls.
'I hate, hate, hate talking about myself,' warns Professor Francois Venter. We are sitting in the immaculate boardroom of Ezintsha, the Wits-based medical research centre that Venter leads.
Ezintsha came to international attention in 2019 after the results of a clinical trial called ADVANCE were published in the New England Journal of Medicine, showing the effectiveness of new HIV therapies and, perhaps more importantly, demonstrating why it is important that clinical trials be conducted in the contexts in which the drugs are mainly consumed.
Venter, by this time, was already well known for his work in HIV, not only for his scientific outputs, but also for taking up cudgels on behalf of people living with HIV.
In a series of recent op-eds, for example, he has excoriated both the President and the health minister for providing scant leadership in the face of the US's defunding of the HIV response in South Africa, comparing their inaction to the infamous Aids denialism of Thabo Mbeki and his health minister, Manto Tshabalala-Msimang.
Venter's response to being singled out is predictable: 'There are so many people in the HIV world who did much more, and more bravely.' It is the refrain of many treatment activists.
Venter is tall, powerfully built. His disposition is nervous, though, his speech often self-effacing, but mention one of his many bugbears and a quiet fury brims.
He is known for speaking without any regard to self-preservation, using what a lecturer friend calls 'borderline cancel language'. Like a good journalist, he calls it as he sees it.
The comparison pleases Venter, who was editor of the campus newspaper, Wits Student, in 1991. He describes his involvement in student politics as an almost involuntary act, akin to staying afloat in a turbulent river, saying: 'As far as I was concerned, there was nowhere for a white person to hide, and joining the fight [against apartheid] was the only moral choice.'
The height of the HIV epidemic
Venter did his 'house job' (residency) at Hillbrow Hospital, which is where he first encountered HIV as a student.
'It was the beginning of that incredible surge in numbers that occurred between 1993 and 1997. The first cases I saw were returning political exiles,' says Venter.
By 1997, the HIV epidemic was at its zenith in South Africa, and hospitals across the country were overwhelmed. He still struggles to forgive the callousness of some senior administrators.
'And looking back, that was the first sign of the absolute arrogance of some of the health people in government. And you see it now in the way foreigners and poor people are treated in the public sector. It is one thing to have no idea how to deal with a problem, but to lack the ability to do any reflection, have any empathy and to self-­correct is so upsetting.'
Venter's interest in HIV was sparked by his experience of looking after a haemophiliac in 1997. He was amazed at the impact of antiretroviral therapy (ART) on his patient.
Jobs followed at the Wits-based Clinical HIV Research Unit with world-­renowned HIV expert Ian Sanne and Professor Helen Rees's Wits Reproductive Health and HIV Initiative, where Venter ran a huge US government-funded HIV-support programme for a decade in several provinces, gaining experience in expanding primary care approaches in chronic diseases.
They were heady times, in which Venter was left disappointed again and again by much of the medical community.
'Other than the rural doctors, who have always fought for their patients, and the HIV Clinicians Society, the healthcare worker organisations were nowhere to be seen,' says Venter, lamenting that little has changed.
'Through Covid-19, and now with the defunding of HIV and scientific research, it is the same people raising their voices and the same organisations sitting on their hands. Worryingly, a lot of the people we are fighting are the same ones who stood in the way of access during the Mbeki era.'
In the nearly three decades since 1997, many important clinical trials, HIV programmes, research papers and court cases have gone under the bridge, and Venter has become part of the moral conscience of South Africa.
Ezintsha, for years based in a Yeoville house, now occupies two floors of a large office block in Parktown, which also houses a new obesity clinic, where Venter sees patients with South Africa's new pandemic.
'The new drugs for obesity are every bit as revolutionary as the HIV drugs,' he says, 'but every bit as fiddly as antiretrovirals were in 2000.'
New studies, using these wonder drugs in people with both HIV and obesity, are being hatched here. Ezintsha's health staff are looking at using HIV lessons to try to improve primary care for diabetes, hypertension and other common diseases in South Africa.
The race to the bottom
We are a long way from the early days. Donor funding, although key to the fight against HIV in South Africa, has also distanced organisations from communities and created a dependency which, after the collapse of the US government's Aids fund, Pepfar and the US International Agency for International Development threatens catastrophe.
'What happened still feels quite unthinkable. On the one hand it feels like 2004, when Mbeki's denial of HIV became national policy and everything felt like it was going backwards. On the other hand it is extremely frustrating that our systems have not been made sustainable, and are now on the brink of collapse as a result of Pepfar having been interwoven with the national HIV programme to such an extent that everything unravels when it is stopped.'
Venter sketches a scenario in which South Africa's HIV response – 'the one effective programme we have' – is misleadingly characterised as 'too expensive' and dragged down to the lowest common denominator, 'leading to the same terrible outcomes you find in crap programmes, like diabetes'.
'A race to the bottom, in other words… We have poor indicators for almost every health metric outside of HIV, TB and vaccines, and even those are now slipping, due to the Health Department dropping the ball.'
Will this grim scenario prevail, or will South African healthcare be shepherded through the labyrinth of budget cuts and misfiring systems? Venter doesn't see why not.
'Our problems are systemic, and we have enough resources and brains to fix them. What is needed is strong leadership, which is something we currently lack,' he says.
'I'll tell you what you do… We all declare our interests, put an end to corruption, and everyone from the President and the minister of health down in government must use the public healthcare system when using their medical aid. If they experience the system first-hand, they will have an immediate investment in assisting those fixing it.
'Stop blaming the private sector and a lack of money for the problem. Start using the innovations South Africans are world leaders in, including data systems. If we do that, I am telling you, we will fix the system in five years.'
Venter, clearly, has already rolled up his sleeves for this new fight. It will be interesting to see who joins him. DM
This story first appeared in our weekly Daily Maverick 168 newspaper, which is available countrywide for R35.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

FW de Klerk Foundation urges South Africa to diversify trade amid US tariffs
FW de Klerk Foundation urges South Africa to diversify trade amid US tariffs

The Star

time14 hours ago

  • The Star

FW de Klerk Foundation urges South Africa to diversify trade amid US tariffs

Bongani Hans | Published 17 hours ago Apartheid's last president, FW De Klerk's foundation has added its voice in calling for South Africa to stop being overly reliant on America and look elsewhere for trade deals amid concerns over President Donald Trump's 30% tariffs on exports. In what could be seen as the country's population bending together against the economic squeezing tariffs, the foundation echoed DA leader John Steenhuisen in calling for the country to spread its wings wider, looking for alternative markets across the world. Steenhuisen, in his capacity as Agriculture minister, said recently that the country is strengthening its trade alliances with the likes of Chile, Peru, and New Zealand 'to jointly lobby for fair and stable trade treatment of fresh produce' through the Southern Hemisphere Association of Fresh Fruit Exporters. He also said the state had finalised new phytosanitary protocols for the export of avocados to China, table grapes to Vietnam and the Philippines, and maize to India. FW de Klerk Foundation's Ismail Joosub called for the strengthening of trading ties ' with our BRICS partners and Africa'. The foundation was concerned about the South African Reserve Bank warning that the tariffs could cost the country around 100,000 jobs, 'hitting our agriculture and automotive sectors the hardest.' South Africa is a member of BRICS, which the US sees as a threat to its global economic and political dominance. 'China's vast market, for instance, can buy more of our minerals, wine, and fruits. 'India, Brazil, and others present growing export destinations if we proactively pursue them,' Joosub said in a statement. He issued the statement on Friday, the same day Trump implemented the tariffs, which he said would be effective on August 7. According to, Charles A. Ray, a chairperson of the US-based Foreign Policy Research Institute's African Program and former US ambassador to Cambodia and Zimbabwe, US was unhappy with South Africa's proximity to China and Russia and its membership with BRICS. He said it ' has since become an alternate political forum to the US-led West, seeking to shift the global order more to the advantage of China and to move away from the US dollar's domination of the global economy'. According to one of Trump's Executive Orders, South Africa was undermining the US's foreign policy and posed threats to the US and its allies' security and interests. ' Our government is already working with industry to find alternative markets for our goods and support affected sectors with contingency plans. 'We should build on this by ramping up trade promotion in Asia, the Middle East and across Africa. 'In short, if one door closes, we must be ready to open many others,' said Joosub. He said another step to protect and grow the economy was to invest in youth, skilling young people by taking advantage of an initiative that China has established through its Luban Workshops, which are vocational training centres in nearly 20 countries. 'South Africa should welcome such initiatives and even expand them here at home, [as] at last year's BRICS summit in Johannesburg, a BRICS Skills Challenge showcased how collaboration in fields like robotics, data science and aerospace can help our youth develop critical skills. 'Millions of talented South African youth remain on the margins, [so] we need to harness their potential through education, training and entrepreneurship support,' he said. Joosub also called for the country to look at technical exchange programs, scholarships, and joint research with programmes with China, India and others to help the country cultivate much-needed skills in engineering, artisans and the innovation sectors. 'By equipping young South Africans with world-class skills, we not only reduce unemployment but also make our economy more competitive globally. 'Our Constitution's preamble enjoins us to ' free the potential of each person , ' and there is no greater potential waiting to be freed than that of our youth,' he said. The foundation was concerned that unemployment was already at 32,9% and youth unemployment exceeded 46%. 'We cannot afford further blows. It's a stark reminder that nearly half of young South Africans struggle to find work,' he said. He said the US was punishing South Africa for its domestic policies, including affirmative action and Black Economic Empowerment, and the country's diplomatic stance on the Russia-Ukraine war and a genocide case against Israel , which he said the US views as creating barriers or running counter to its interests. 'We should be candid: while the American approach is blunt, it has exposed fault lines in our own house. 'This tariff standoff is, in part, a reaction to our policy choices - and it compels us to reflect on whether those choices are achieving their intended goals,' said Joosub. President Cyril Ramaphosa believes his administration will still be able to find a way out of the 30% tariffs before August 7. [email protected]

Promising new monthly pill moves to phase-three trials in HIV prevention revolution
Promising new monthly pill moves to phase-three trials in HIV prevention revolution

Daily Maverick

time19 hours ago

  • Daily Maverick

Promising new monthly pill moves to phase-three trials in HIV prevention revolution

A new antiretroviral pill has shown promising results and is now entering large-scale trials. Spotlight reports on new findings on the pill. There are several antiretroviral formulations proven to prevent HIV infection: a daily pill, two different jabs that offer protection for two and six months, respectively, and a vaginal ring for women that has to be replaced monthly. In a few years, a long-acting pill may join the ranks, if it works. The pill, for now called MK-8527, has the potential to prevent HIV infection for up to a month in its current formulation. It is a nucleoside reverse transcriptase translocation inhibitor, which means it disrupts a specific step in the cycle by which the virus makes copies of itself. The pill is now moving on to pivotal phase-three trials after promising results from a smaller phase-two study presented at the International Aids Society (IAS) conference held in Kigali, Rwanda. The phase-two study, conducted in trial sites in South Africa, the US and Israel, showed that MK-8527 was well tolerated and had a safety profile similar to a placebo. It also showed the levels of the antiretroviral were at the required levels in participants' bodies, although the study was not designed to determine whether it is effective. Whether MK-8527 actually prevents HIV infection will now be tested in two large phase-three studies in multiple countries, including South Africa. In these studies, the efficacy of the monthly pill will be compared with that of a daily HIV prevention pill already widely available in South Africa's public sector. The daily pill contains the antiretroviral drugs tenofovir disoproxil fumarate and emtricitabine. Latest findings The phase-two study looked at three different doses of the monthly pill – 3mg, 6mg and 12mg – as well as a placebo. The 350 participants, about one third of whom were from South Africa, were given one pill (either an active pill or placebo) every month for six months. They were monitored for at least two months afterwards. None of the participants acquired HIV during the study. The researchers enrolled adults who were at a low risk of being exposed to HIV and excluded pregnant and breast-feeding women, and people who had previously used MK-8527 or a similar antiretroviral drug called islatravir, said Dr Kenneth Mayer, a professor of medicine at Harvard Medical School, who presented the findings in Kigali last week. The levels of the antiretroviral in the blood of all the participants were measured on day one and two, on the last day of taking the pill, and again at the first follow-up visit after stopping the pill. Based on these results, Mayer said there doesn't appear to be a build-up of drug in the body that might prove toxic over time. This supports evaluating the use of a monthly pill over a longer time period (than the six months in the study), he said, 'without concern that increasing drug levels will cause toxicity after a longer period of monthly administration'. About 20 participants across the three active pill arms were monitored more closely to measure the levels of MK-8527 triphosphate in their blood at each study visit. Results showed that the 6mg and 12mg doses kept levels at 'above the threshold of protection' for just more than 28 days. Apart from staying in the body for a long time, it also seems that the drug works very quickly. Mayer told delegates that modelling, informed by measurements of how the drug is taken up in the body, suggests that the pill could offer protection against HIV infection potentially as soon as an hour after taking it. How safe is it? Since HIV-prevention medicines are offered to healthy people, or at least people who are not living with HIV, the safety of these drugs is particularly closely watched. This is because the risk-benefit trade-off is different than it is for people who are living with HIV and might be willing to accept more side effects if it means the medicines are keeping them alive and healthy. The most common side effects reported in the phase-two study were headache, nausea and fatigue. The rates of these side effects were similar between participants who got the antiretroviral pills and those who got the placebo. One concerning event in the 3mg arm was a spontaneous abortion at six weeks into a pregnancy. According to Mayer, this was seen as a serious adverse event related to the study drug. He explained that although he didn't have all the details from the safety records, he understood that the participant had previously experienced pregnancy losses, but most if not all were induced. 'She did not have any other medical conditions that were associated with adverse pregnancy outcomes, so we had to consider the event related to the study medication, out of an abundance of caution, since this was a safety trial,' Mayer told Spotlight. Participants had tests done to check their CD4 levels (an indicator of immune system health) and lymphocyte (a type of white blood cell) counts at each study visit. A significant drop in either or both of these indicators would lead to the drug being stopped. Mayer explained that CD4 and lymphocyte counts were specifically monitored because the monthly pill has the same mechanism of action as another drug called islatravir, which in high doses resulted in a decrease in both these counts. 'MK-8527 is chemically different [to islatravir], but since they both inhibit these steps in the virus life cycle, it was important to monitor these parameters during the safety trial,' Mayer said. 'Fortunately, we did not see a significant trend affecting these clinical lab values.' Only two participants dropped out of the study because of side effects in the two higher dose groups. One person from the 12mg arm dropped out because of hypaesthesia, which is a loss of sensation or numbness. Another person in the 6mg arm left because their CD4 and/or lymphocyte count dropped to levels that met the study's rules for stopping the pill. In the next few years, the larger phase-three studies should provide much more extensive and detailed data on the safety and side effect profile of MK-8527. Is there a place for a monthly pill? At last year's Aids conference, delegates celebrated the success of the PURPOSE 1 and 2 trials that showed remarkable protection offered by lenacapavir, a long-acting HIV-prevention jab. It reliably offers protection against HIV infection for six months at a time. In June, it was approved for use by the US Food and Drug Administration for HIV prevention. It was previously approved only as treatment for hard-to-treat HIV. In July, the World Health Organization released guidelines recommending its use for HIV prevention. Lenacapavir has not yet been registered by the South African Health Products Regulatory Authority. Although most of the focus in HIV circles is still on lenacapavir, experts told Spotlight that even though MK-8527 may potentially only protect against HIV for about a month at a time, it could still be a useful option for HIV prevention. 'There is a real place for a long-acting, non-injectable PrEP [pre-exposure prophylaxis)]. And we believe there really is a role for a monthly pill – they are small [and] easy to take,' said Professor Linda-Gail Bekker, CEO of the Desmond Tutu Health Foundation and director of the Desmond Tutu HIV Centre. 'There is potential for giving all 12 pills in one go or three pills in one go, or any variation,' she added. This potential future option, provided it works, comes at a time when there is plenty of financial upheaval with the sudden termination of research funding and aid by the US. For Bekker, the hope is that a pill for prevention may prove to be an affordable and accessible option. Mitchell Warren, executive director of the Aids Vaccine Advocacy Coalition, told Spotlight that a monthly pill for prevention will not replace but add to the existing basket of HIV prevention options. 'It may help people who have a hard time adhering to daily pill-taking. It will help people who don't want to get an injection,' he said. 'It [MK-8527] is just 12 pills a year – that's a remarkable advance.' Next steps — the phase-three trials Merck, the pharmaceutical company that's developing the pill, announced that, later this year, MK-8527 will be evaluated at clinical trials sites across the globe in two large phase-three studies called EXPrESSIVE-10 and EXPrESSIVE-11. The studies will determine the safety and tolerability of the monthly pill, and whether it works as well as or better than the standard of care at preventing HIV. 'If MK-8527 is found to be comparable or superior to daily oral PrEP, it could be a game-changer for the HIV prevention field, offering people a simple way to protect themselves which would not require daily medication or injections,' said Mayer. Warren said that, like the PURPOSE studies, if a woman becomes pregnant during the study, she will have the option to give consent again and continue. This allows researchers to collect data on pregnant and breast-feeding women too. Although results from the phase-three studies are at least two years away, Merck appears set to try to roll out the product as soon as possible if it is successful. 'We are pursuing very optimistic and aggressive timelines,' said Dr Rebeca Plank, a scientist in clinical research at Merck, during an IAS press conference. DM This article first appeared in Spotlight.

Ukrainian drone strikes kill 3 in Russia
Ukrainian drone strikes kill 3 in Russia

Eyewitness News

timea day ago

  • Eyewitness News

Ukrainian drone strikes kill 3 in Russia

MOSCOW - Ukrainian drone strikes killed three people and wounded two others overnight in western Russia, regional governors said on Saturday. One woman was killed and two other people were wounded in an attack on an enterprise in Penza, the region's governor, Oleg Melnichenko, wrote on Telegram. An elderly man was killed inside a house that caught fire due to falling drone debris in the Samara region, governor Vyacheslav Fedorishchev posted on Telegram. In the Rostov region, a guard at an industrial facility was killed after a drone attack and a fire in one of the site's buildings, acting Rostov governor Yuri Sliusar said. "The military repelled a massive air attack during the night," destroying drones over seven districts, Sliusar posted on Telegram. Russia's defence ministry said its air defence systems had destroyed 112 Ukrainian drones over Russian territory -- 34 over the Rostov region -- in a nearly nine-hour period, from Friday night to Saturday morning. In Ukraine's central-eastern Dnipropetrovsk region, overnight Russian drone attacks left three people wounded, governor Sergiy Lysak wrote on Telegram. Several buildings, homes and cars were damaged, he said. Russian forces have claimed advances in Dnipropetrovsk, recently announcing the capture of two villages there, part of Moscow's accelerated capture of territory in July, according to AFP's analysis of data from the US-based Institute for the Study of War (ISW). Kyiv denies any Russian presence in the Dnipropetrovsk area. Russian President Vladimir Putin, who has consistently rejected calls for a ceasefire in the more than three-year conflict, said Friday that he wanted peace but that his demands for ending Moscow's military offensive were "unchanged". Those demands include that Ukraine abandon territory and end ambitions to join NATO. Ukrainian President Volodymyr Zelensky, meanwhile, said only Putin could end the war and renewed his call for a meeting between the two leaders. "The United States has proposed this. Ukraine has supported it. What is needed is Russia's readiness," he wrote on X.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store